Protara Therapeutics, Inc. TARA 深 沪
交易中 10-01 10:18:03 美东时间
2.955
-0.095
-3.11%
华盛通- 最 高3.10
- 今 开3.06
- 成交量 53.04万股
- 最 低 2.955
- 昨 收 3.05
- 总市值 1.75亿
- 52周最高 7.82
- 市盈率 静 --
- 换手率 0.90%
- 52周最低 2.955
- 委 比 -8.70%
- 总股本 5909.55万
- 历史最高 800.00
- 量 比 2.89
- 振 幅 4.75%
- 历史最低 1.04
- 每 手 1
- 风险率 0.98%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Protara Therapeutics, Inc. (Nasdaq: TARA) announced that its management will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, at 2:00 pm ET. A live webcast will be available on the Company’s website, and an archive will be accessible for a limited time. Protara is a clinical-stage biotech company focused on developing therapies for cancer and rare diseases, including its lead candidate TARA-002 for no...
09-08 20:05
Protara Therapeutics Q2 EPS $(0.36) Misses $(0.33) Estimate
Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.33) by 9.09 percent. This is a 2.86 percent decrease over losses of $(0.35) per share from the same period last year.
08-11 20:07
Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update
Corbus Pharmaceuticals reported progress in its oncology and obesity pipeline, obtaining FDA clearance for the registrational study of CRB-701 in oropharyngeal cancer and completing the last patient visit in the CANYON-1 trial of CRB-913 for obesity. The company also appointed new leadership to strengthen its team. Financially, Corbus reported a net loss of $35 million for the second quarter, with $117.9 million in cash on hand.
08-06 12:00
Corbus Pharmaceuticals appoints Leonardo Viana Nicacio as Chief Medical Officer
Corbus Pharmaceuticals Holdings (CRBP) announced the appointment of Leonardo Viana Nicacio as Chief Medical Officer. Nicacio brings over 20 years of pharmaceutical and oncology experience, notably ser...
07-06 20:14
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer
Corbus Pharmaceuticals appoints Dr. Leonardo Viana Nicacio as Chief Medical Officer, bringing extensive experience in solid tumor drug development, including ADCs like TIVDAK® for metastatic cervical cancer. The company is set to initiate the TEMPO-1 registrational study for CRB-701 in 2L oropharyngeal squamous cell carcinoma (OPSCC) this summer. Dr. Nicacio emphasizes advancing CRB-701 and CRB-913 to address unmet needs in oncology and obesity, ...
07-06 12:00
Protara Therapeutics Announces Key Medical Leadership Transition
Protara Therapeutics ( ($TARA) ) has issued an announcement. On June 26, 2026, ...
06-30 05:30
Protara Therapeutics Stockholders Approve Governance and Share Increases
Protara Therapeutics ( ($TARA) ) just unveiled an announcement. Protara Therape...
06-16 05:06
Protara Therapeutics Enters $100M At-the-Market Equity Sales Agreement With TD Cowen
$100,000,000Common StockWe have entered into a sales agreement with TD Securities (USA) LLC, or TD Cowen, dated May 13, 2026, or the Sales Agreement, relating to the sale of shares of our common stock, par value $0.001
05-29 05:20
美股大行评级 | Cava、CrowdStrike、Keysight获多家大行上调目标价；家得宝绩后遭多家大行下调目标价
今日重点评级关注：Oppenheimer：维持Protara Therapeutics"跑赢大市"评级，目标价从25美元升至28美元；Piper Sandler：维持Bright Minds Biosciences"超配"评级，目标价从190美元升至220美元
05-21 12:05
Protara Therapeutics Reports 55% Complete Response Rate In Bladder Cancer Study
Protara reports updated Phase 2 data showing durable responses and favorable safety for TARA-002 in bladder cancer patients.
05-15 23:36
